Bergen, Norway, 5 November 2024- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, will be announcing its results for the third quarter 2024 on Wednesday 13 November 2024. BerGenBio’s senior management team will provide a business update at 10:00 am CET. The presentation will webcast live. To … Read more
Bergen, Norway – 19 September 2024: BerGenBio ASA (OSE:BGBIO) will be holding a Extraordinary General Meeting virtually on 10 October 2024 at 10:00 hours (CEST). The notice, registration form and power of attorney are attached to this release. The notice will be sent to all registered shareholders and the notice in addition to other attachments … Read more
Bergen, Norway – 28 April 2023: BerGenBio ASA (OSE:BGBIO) will be holding its Annual General Meeting virtually on 22 May 2022 at 16:00 hours (CEST). The notice, registration form, power of attorney and proposal from Nomination Committee are attached to this release. The notice will be sent to all registered shareholders and is available on … Read more
Bergen, Norway, 3 November 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, will be announcing its results for the third quarter 2020 on Tuesday 17 November 2020. A webcast presentation by BerGenBio’s senior management team will take place at 10:00 am CET. The live … Read more
Bergen, Norway, 10 August 2020 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for unmet medical need, will be announcing its results for the second quarter 2020 on Tuesday 18 August 2020. A webcast presentation by BerGenBio’s senior management team will take place at 10:00 am CET. The live … Read more
Bergen, Norway, 13 May 2020 – BerGenBio ASA (OSE:BGBIO), will announce its results for the first quarter 2020 on Tuesday 19 May 2020. A webcast presentation by BerGenBio’s senior management team will take place at 10 am CET. The presentation will webcast live and the link will be available at www.bergenbio.com in the section Investors/Financial Reports. A recording … Read more
Bergen, Norway, March 30, 2020 – BerGenBio, a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, announces today that Richard Godfrey, Chief Executive Officer, will present at the upcoming Solebury Trout Virtual Investor Conference. The 25 minute presentation includes an interactive Q&A with participants prompted to submit questions electronically. Details are as … Read more
Bergen, Norway, 24 February 2020 – Annual General Meeting in BerGenBio ASA will be held on 16 March 2019 at 17:00 hours (CET) at Clarion Hotel Bergen Airport, Flyplassveien 551, 5869 Bergen. The notice, registration form, power of attorney and proposal from Nomination Committee are attached to this release. The notice will be sent to all … Read more
Bergen, Norway, 3 February 2020 – BerGenBio ASA (OSE:BGBIO), will announce its results for the fourth quarter and full year 2019 on Tuesday 11 February 2020. A presentation by BerGenBio’s senior management team will take place at 10 am CET at: Hotel ContinentalStortingsgaten 24/26Oslo The presentation will webcast live and the link will be available at www.bergenbio.com in … Read more
Bergen, Norway, 7 November 2019 – BerGenBio ASA (OSE:BGBIO), will announce its results for the third quarter on Tuesday 19 November 2019. A presentation by BerGenBio’s senior management team will take place at 10am CET at: Arctic SecuritiesHaakon VIIs gate 5Oslo The presentation will webcast live and the link will be available at www.bergenbio.com in the section Investors/Financial … Read more
soug@oncoinvent.com
Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.
Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997
mansson@oncoinvent.com
Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.
Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.